These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 30714719)

  • 21. Parkinson's disease from the gut.
    Liddle RA
    Brain Res; 2018 Aug; 1693(Pt B):201-206. PubMed ID: 29360467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein.
    Iravanpour F; Farrokhi MR; Jafarinia M; Oliaee RT
    Hum Cell; 2024 Jan; 37(1):1-8. PubMed ID: 37735344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct pattern of enteric phospho-alpha-synuclein aggregates and gene expression profiles in patients with Parkinson's disease.
    Barrenschee M; Zorenkov D; Böttner M; Lange C; Cossais F; Scharf AB; Deuschl G; Schneider SA; Ellrichmann M; Fritscher-Ravens A; Wedel T
    Acta Neuropathol Commun; 2017 Jan; 5(1):1. PubMed ID: 28057070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The central theme of Parkinson's disease: α-synuclein.
    Ozansoy M; Başak AN
    Mol Neurobiol; 2013 Apr; 47(2):460-5. PubMed ID: 23180276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders.
    Gelpi E; Navarro-Otano J; Tolosa E; Gaig C; Compta Y; Rey MJ; Martí MJ; Hernández I; Valldeoriola F; Reñé R; Ribalta T
    Mov Disord; 2014 Jul; 29(8):1010-8. PubMed ID: 24395122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of alpha-synuclein aggregates.
    Wakabayashi K; Tanji K; Mori F; Takahashi H
    Neuropathology; 2007 Oct; 27(5):494-506. PubMed ID: 18018486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
    Xu S; Chan P
    Biomolecules; 2015 Jun; 5(2):1122-42. PubMed ID: 26057626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha Synuclein Toxicity and Non-Motor Parkinson's.
    Mazzotta GM; Conte C
    Cells; 2024 Jul; 13(15):. PubMed ID: 39120295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
    Orimo S
    Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of pathogenic potential of peripheral α-synuclein aggregates from Parkinson's disease patients.
    Recasens A; Carballo-Carbajal I; Parent A; Bové J; Gelpi E; Tolosa E; Vila M
    Acta Neuropathol Commun; 2018 Feb; 6(1):8. PubMed ID: 29422109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are Therapies That Target α-Synuclein Effective at Halting Parkinson's Disease Progression? A Systematic Review.
    Rodger AT; ALNasser M; Carter WG
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-motor parkinsonian pathology in aging A53T α-synuclein mice is associated with progressive synucleinopathy and altered enzymatic function.
    Farrell KF; Krishnamachari S; Villanueva E; Lou H; Alerte TN; Peet E; Drolet RE; Perez RG
    J Neurochem; 2014 Feb; 128(4):536-46. PubMed ID: 24117685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Glial Activation and α-Synuclein Pathology in Parkinson's Disease.
    Wang R; Ren H; Kaznacheyeva E; Lu X; Wang G
    Neurosci Bull; 2023 Mar; 39(3):479-490. PubMed ID: 36229715
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Manne S; Kondru N; Jin H; Anantharam V; Huang X; Kanthasamy A; Kanthasamy AG
    Mov Disord; 2020 Feb; 35(2):268-278. PubMed ID: 31758740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lewy bodies in Parkinson's disease: histological, immunohistochemical, and interferometric examinations].
    Voronkov DN; Salkov VN; Anufriev PL; Khudoerkov RM
    Arkh Patol; 2018; 80(4):9-13. PubMed ID: 30059066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.